Investigational drug · Phase 2
TEV-56286
Also called: Emrusolmin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple System Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "TEV-56286"
First trial start
2024
Oct 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TEV-56286", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple System Atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "TEV-56286" as an intervention, largest first.
- A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System AtrophyPivotal-lookingActive, not recruiting
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT06568237 · 349 participants · Start Oct 2, 2024 · Primary completion Sep 15, 2027
Drug: TEV-56286; Placebo · For: Multiple System Atrophy
Sites: La Jolla, California; Los Angeles, California; Washington D.C., District of Columbia · 61 sites in all
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT07197866 · 200 participants (planned) · Start Sep 30, 2025 · Primary completion May 3, 2029
Drug: TEV-56286 · For: Multiple System Atrophy
Sites: La Jolla, California; Boca Raton, Florida; Tampa, Florida · 41 sites in all
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT07674940 · 69 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 15, 2027
Drug: TEV-56286; Placebo · For: Healthy Volunteers
Sites: Miramar, Florida
MODAG GmbHIndustry
NCT05532358 · 54 participants · Start Sep 12, 2022 · Primary completion Jan 28, 2023
Drug: anle138b (TEV-56286); Fluvoxamine 100 mg QD for 5 days · For: Healthy Volunteers
Sites: Nottingham, United Kingdom
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT06911567 · 47 participants · Start Mar 10, 2025 · Primary completion May 22, 2025
Drug: TEV-56286 Test; TEV-56286 Reference · For: Healthy Participants
Sites: Miramar, Florida
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT06627231 · 8 participants · Start Oct 8, 2024 · Primary completion Nov 29, 2024
Drug: TEV-56286; [14C]-TEV-56286 · For: Healthy Participants
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease.
da Silva Padilha M, Koyuncu S, Chabanis E, et al. · EMBO Mol Med 2026
Also in development for Multiple System Atrophy
- AmlenetugLu AF82422Phase 32 trials
H. Lundbeck A/S · Multiple System Atrophy
- PBT434ATH434Phase 23 trials
Alterity Therapeutics · Multiple System Atrophy
- Foralumab NasalPhase 22 trials
Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- exidavnemabPhase 21 trial
BioArctic AB · Parkinson Disease, Multiple System Atrophy
- TAK-341MEDI1341Phase 21 trial
Takeda · Multiple System Atrophy
- YA-101Phase 21 trial
Dasher Neuroscience Inc. · Multiple System Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Teva.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.